Literature DB >> 29872561

Epigenetic anticancer agents cause HMGB1 release in vivo.

Peng Liu1,2,3,4,5,6, Liwei Zhao1,2,3,4,5,6, Friedemann Loos2,3,4,5,6, Kristina Iribarren2,3,4,5,6, Oliver Kepp2,3,4,5,6, Guido Kroemer2,3,4,5,6,7,8.   

Abstract

A systematic search for anticancer agents that may induce the release of high mobility group box 1 (HMGB1) protein from cells into the extracellular space has led to the identification of several drugs capable of elevating plasma HMGB1 levels in vivo, in mice. Such agents include bona-fide immunogenic cell death inducers such as oxaliplatin, as well as a series of epigenetic modifiers, namely azacitidine, decitabine, and suberoylanilide hydroxamic acid (SAHA).

Entities:  

Keywords:  RUSH; biotin; cancer; chemotherapy; immunosurveillance

Year:  2018        PMID： 29872561      PMCID： PMC5980346          DOI： 10.1080/2162402X.2018.1431090

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Immunogenic cell death in cancer and infectious disease.

Authors:  Lorenzo Galluzzi; Aitziber Buqué; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2016-10-17       Impact factor: 53.106

2.  Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.

Authors:  Ailsa J Christiansen; Alison West; Kellie-Marie Banks; Nicole M Haynes; Michele W Teng; Mark J Smyth; Ricky W Johnstone
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-22       Impact factor: 11.205

3.  An intact immune system is required for the anticancer activities of histone deacetylase inhibitors.

Authors:  Alison C West; Stephen R Mattarollo; Jake Shortt; Leonie A Cluse; Ailsa J Christiansen; Mark J Smyth; Ricky W Johnstone
Journal:  Cancer Res       Date:  2013-10-24       Impact factor: 12.701

4.  The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro.

Authors:  Jürgen Sonnemann; Stephanie Gressmann; Sabine Becker; Susan Wittig; Mareike Schmudde; James F Beck
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-10       Impact factor: 3.333

Review 5.  Immunological effects of hypomethylating agents.

Authors:  Katherine E Lindblad; Meghali Goswami; Christopher S Hourigan; Karolyn A Oetjen
Journal:  Expert Rev Hematol       Date:  2017-07-03       Impact factor: 2.929

Review 6.  Natural and therapy-induced immunosurveillance in breast cancer.

Authors:  Guido Kroemer; Laura Senovilla; Lorenzo Galluzzi; Fabrice André; Laurence Zitvogel
Journal:  Nat Med       Date:  2015-10       Impact factor: 53.440

Review 7.  HMGB1 as biomarker and drug target.

Authors:  Emilie Venereau; Federica De Leo; Rosanna Mezzapelle; Giorgia Careccia; Giovanna Musco; Marco E Bianchi
Journal:  Pharmacol Res       Date:  2016-07-01       Impact factor: 7.658

Review 8.  Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.

Authors:  Lorenzo Galluzzi; Aitziber Buqué; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Cancer Cell       Date:  2015-12-14       Impact factor: 31.743

Review 9.  Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance.

Authors:  Norma Bloy; Pauline Garcia; Céline M Laumont; Jonathan M Pitt; Antonella Sistigu; Gautier Stoll; Takahiro Yamazaki; Eric Bonneil; Aitziber Buqué; Juliette Humeau; Jan W Drijfhout; Guillaume Meurice; Steffen Walter; Jens Fritsche; Toni Weinschenk; Hans-Georg Rammensee; Cornelis Melief; Pierre Thibault; Claude Perreault; Jonathan Pol; Laurence Zitvogel; Laura Senovilla; Guido Kroemer
Journal:  Immunol Rev       Date:  2017-11       Impact factor: 12.988

10.  Identification of pharmacological agents that induce HMGB1 release.

Authors:  Peng Liu; Liwei Zhao; Friedemann Loos; Kristina Iribarren; Sylvie Lachkar; Heng Zhou; Lígia C Gomes-da-Silva; Guo Chen; Lucillia Bezu; Gaelle Boncompain; Franck Perez; Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal:  Sci Rep       Date:  2017-11-02       Impact factor: 4.379
  10 in total
  6 in total

Review 1.  A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers.

Authors:  Oliver Kepp; Allan Sauvat; Marion Leduc; Sabrina Forveille; Peng Liu; Liwei Zhao; Lucillia Bezu; Wei Xie; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2019-04-26       Impact factor: 8.110

Review 2.  Trial watch: Peptide-based vaccines in anticancer therapy.

Authors:  Lucillia Bezu; Oliver Kepp; Giulia Cerrato; Jonathan Pol; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-09-06       Impact factor: 8.110

Review 3.  Immunological Effects of Epigenetic Modifiers.

Authors:  Lucillia Bezu; Alejandra Wu Chuang; Peng Liu; Guido Kroemer; Oliver Kepp
Journal:  Cancers (Basel)       Date:  2019-12-01       Impact factor: 6.639

Review 4.  Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.

Authors:  Isaure Vanmeerbeek; Jenny Sprooten; Dirk De Ruysscher; Sabine Tejpar; Peter Vandenberghe; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2020-01-09       Impact factor: 8.110

5.  Antibody-drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties.

Authors:  Anette Sommer; Sandra Berndt; Hans-Georg Lerchen; Sabrina Forveille; Allan Sauvat; Dominik Mumberg; Guido Kroemer; Oliver Kepp
Journal:  Oncoimmunology       Date:  2022-02-09       Impact factor: 8.110

Review 6.  Recent Advances in the Chemistry and Therapeutic Evaluation of Naturally Occurring and Synthetic Withanolides.

Authors:  Amandeep Singh; Asif Raza; Shantu Amin; Chendil Damodaran; Arun K Sharma
Journal:  Molecules       Date:  2022-01-28       Impact factor: 4.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.